IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation

Transplantation Proceedings

Volumn 33, Issue 1-2, 2001, Pages 1433-1434

  Langrehr, J M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RISK; TACROLIMUS;

EID: 0035077067     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(00)02541-0     Document Type: Conference Paper

References (5)

1. Neuhaus P, Bechstein WO, Blumhardt G, et al: Transplantation 55:1320, 1993
2. European FK506 Multicentre Liver Study Group: Lancet 344:423, 1994
3. The US Multicenter FK506 Liver Study Group: N Engl J Med 331:1110, 1994
4. Neuhaus P, et al: Ann Surg 219:426, 1994
5. Langrehr JM, Nüssler NC, Neumann U, et al: Transplantation 63:1772, 1997